Physician profile
Natalie Gavin
NPI 1952135972
$586.97
in general payments reported to CMS, 2019-2025
12 companies · $587 in 2025
The $587 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $587.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $586.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $131.21 | 2025 | Darzalex, Talvey, Erleada |
| Incyte Corporation | $78.12 | 2025 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $68.73 | 2025 | Hyqvia, Fruzaqla |
| Astrazeneca Pharmaceuticals Lp | $61.78 | 2025 | Wainua, Tagrisso |
| Beone Medicines USA, INC. | $58.29 | 2025 | Brukinsa |
| Jazz Pharmaceuticals INC. | $38.69 | 2025 | |
| Springworks Therapeutics, INC. | $37.72 | 2025 | Ogsiveo |
| Daiichi Sankyo INC. | $27.16 | 2025 | Vanflyta |
| Amgen INC. | $26.30 | 2025 | Prolia, Evenity |
| Astellas Pharma US INC | $25.27 | 2025 | Padcev |
| Biogen, INC. | $17.60 | 2025 | Tysabri |
| Melinta Therapeutics, LLC | $16.10 | 2025 | Rezzayo, Orbactiv, Kimyrsa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Gavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.